ISCTM 2022: Scientific Posters Compilation September 19, 2022 Signant Health Posted in Scientific Advisory Share: LinkedIn0Tweet0 Signant’s neuroscience team and CNS experts presented scientific posters at the 2022 Autumn Conference hosted by the International Society for CNS Clinical Trials and Methodology. The posters presented original research on a variety of topics related to the Positive and Negative Syndrome Scale (PANSS), including the potential impact of baseline PANSS symptom domain severity on interview duration and abnormal patterns of variability such as post-baseline 30/30 PANSS identical ratings. Separately, we examined whether a 10-item PANSS optimized for pediatric trials would perform similarly to the 30-item PANSS in an independent placebo-controlled multi-site trial. Other posters delved into research on the Mini-Mental State Exam (MMSE) for dementia, including the association between the MMSE interview duration and the presence of administration and/or scoring errors, and the impact of the number of per rater MMSE administrations on the probability of identifying an administration or scoring MMSE error. Browse through each poster below and meet our experts to learn how Signant has been optimizing CNS clinical research for over 20 years. The Impact of Baseline PANSS Factor Scores on the Incidence of Post-Baseline Identical RatingsExploring the Impact of MMSE Assessment Duration on Scoring and Administration ErrorsOptimized 10 Item PANSS for Pediatric Trials: Comparison to 30 Item Version in a Multi-Site Trial for Adolescent SchizophreniaThe Impact of Number of Prior In-Study MMSE Administrations on the Presence of MMSE Scoring or Administration Errors in Dementia Clinical TrialsDoes Baseline Symptom Domain Severity Predict Interview Duration in Acute Schizophrenia Clinical Trials? An Exploratory Retrospective Analysis Signant Health facebook twitter google-plus linkedin Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently generate quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 20 years, over 400 sponsors and CROs of all sizes – including all of Top 20 pharma – have trusted Signant Health solutions for remote and site-based eCOA, eConsent, IRT, supply chain management, and data quality analytics. Recent Posts Clinical Supplies Application Programming Interfaces (APIs) in Randomization and Trial Supply Management (RTSM) Aug 25, 2022 Susmita Petkar Learn more Scientific Advisory AAIC 2022: Scientific Posters Compilation Aug 19, 2022 Signant Health Learn more eCOA 5 Recommendations for Electronically Migrating and Implementing ClinROs Aug 10, 2022 Dan DeBonis Learn more eCOA Innovation: Using Smartphone Sensors to Instrument At-Home Stair-Climbing Performance Tests Aug 03, 2022 Bill Byrom Learn more Scientific Advisory Get to Know the SME – Lew Fredane Aug 02, 2022 Signant Health Learn more
Signant’s neuroscience team and CNS experts presented scientific posters at the 2022 Autumn Conference hosted by the International Society for CNS Clinical Trials and Methodology. The posters presented original research on a variety of topics related to the Positive and Negative Syndrome Scale (PANSS), including the potential impact of baseline PANSS symptom domain severity on interview duration and abnormal patterns of variability such as post-baseline 30/30 PANSS identical ratings. Separately, we examined whether a 10-item PANSS optimized for pediatric trials would perform similarly to the 30-item PANSS in an independent placebo-controlled multi-site trial. Other posters delved into research on the Mini-Mental State Exam (MMSE) for dementia, including the association between the MMSE interview duration and the presence of administration and/or scoring errors, and the impact of the number of per rater MMSE administrations on the probability of identifying an administration or scoring MMSE error. Browse through each poster below and meet our experts to learn how Signant has been optimizing CNS clinical research for over 20 years. The Impact of Baseline PANSS Factor Scores on the Incidence of Post-Baseline Identical RatingsExploring the Impact of MMSE Assessment Duration on Scoring and Administration ErrorsOptimized 10 Item PANSS for Pediatric Trials: Comparison to 30 Item Version in a Multi-Site Trial for Adolescent SchizophreniaThe Impact of Number of Prior In-Study MMSE Administrations on the Presence of MMSE Scoring or Administration Errors in Dementia Clinical TrialsDoes Baseline Symptom Domain Severity Predict Interview Duration in Acute Schizophrenia Clinical Trials? An Exploratory Retrospective Analysis Signant Health facebook twitter google-plus linkedin Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently generate quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 20 years, over 400 sponsors and CROs of all sizes – including all of Top 20 pharma – have trusted Signant Health solutions for remote and site-based eCOA, eConsent, IRT, supply chain management, and data quality analytics.